



# Annual General Meeting Presentation

James Bonnar  
Chief Executive Officer

20 November 2023 | Sydney NSW

# Important Notice & Disclaimer

---

This presentation has been prepared by Nyrada Inc (**NYR or the Company**). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice, and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.


# Nyrada's Vision, Strategy, and Values

 <p><b>Our vision</b></p>	<p>To become a high-growth pharmaceutical company specialising in the discovery and development of novel treatments.</p>
 <p><b>Our strategy</b></p>	<p>To develop treatments for diseases where there is an unmet clinical need, or where current treatments are suboptimal, and to monetise the value of these treatments through advancing clinical drug candidates towards out-licensing.</p>
 <p><b>Advancing our strategy</b></p>	<p>Delivering upon our vision and strategy through our two current target markets - for brain injury via a TRPC ion channel blocker, and for cholesterol-lowering via an oral PKSK9 inhibitor.</p>

	<p><b>Better Health Outcomes</b></p>	<p>Improving patient health is at the heart of everything we do.</p>
	<p><b>Straight Talking</b></p>	<p>We say what we mean and deliver on our promises, both to each other and our stakeholders. We are transparent and act with integrity in everything we do.</p>
	<p><b>Diversity is a Strength</b></p>	<p>We accept our differences and recognise that a variety of experiences and backgrounds creates a stronger team. We know we achieve more working together than alone.</p>
	<p><b>Innovation Excellence</b></p>	<p>We leverage insights and outside-the-box thinking to turn complex problems into simple solutions. We seek to push the boundaries to truly see what's possible.</p>
	<p><b>Resilience</b></p>	<p>We are quick to anticipate obstacles and can pivot and adapt to ensure we stay on course. We are agile in our thinking and embrace different points of view.</p>

## Commercially Focused Business Model with Structural Strengths

We aim to create value for patients and shareholders by advancing optimized, clinic-stage drug candidates towards out-licensing.



# Key Programs and Target Markets



Drug Candidate	Indication	Aim	Target Market (US)	Status
<b>Neurology</b> <b>TRPC 3/6/7 blocker</b>	Brain Injury	First-in-class treatment to prevent secondary brain injury following moderate-severe TBI, concussion, or stroke	<b>&gt;3m</b> Patients / year <sup>1</sup>	GLP Studies ongoing Phase I Study: 2H CY2024
<b>Cardiovascular</b> <b>Oral PCSK9 inhibitor</b>	Cholesterol Lowering	Best-in-class small molecule drug to disrupt and broaden the class in CV management	<b>&gt;18m</b> Patients <sup>2</sup>	Analogue library review Low-cost background works



# Brain Injury Drug Program

---

Novel small molecule TRPC 3/6/7 blocker



# Brain Injury Market

Population, Problem, Opportunity



Each year

**~5.5 million**

People suffer a severe TBI<sup>3</sup>

**55 million**

People are living with the effects of medically assessed TBI<sup>3</sup>

Each year

**+12.2 million**

suffer a stroke<sup>4</sup>

**One drug class for stroke (tPA)**  
suitable for >15% of patients

## TBI Treatment Market

- USD 6.7 billion sales revenue in 2020 (US, UK, Europe, Japan)<sup>5</sup>
- Sales revenue **CAGR 5%** to 2030<sup>5</sup>

## Stroke Drug Market (tPA)


- USD 3.4 billion global revenue in 2018<sup>6</sup>
- Sales revenue **CAGR 7%** to 2027<sup>6</sup>

## Problem and Opportunity



- **Unmet clinical need** with no approved drugs for TBI and limited treatment options for stroke
- **Effective treatment** will **improve patient outcomes** and **reduce high costs** associated with long-term care of brain injury survivors
- Moderate to severe TBI is an **orphan indication**

Nyrada is developing a first-in-class **neuroprotectant drug to prevent secondary injury**

# Brain Injury Trajectory, Patient Outcomes, Treatment Aims



## Serial reconstruction from MRI



**Nyrada drug NYR-BI03**  
An acute 3-day intravenous treatment

- Reduce secondary injury resulting from TBI or stroke
- Improve survivability, limit disability
- Improve quality of life

# Phase I Study Design

**OBJECTIVES** To assess the safety, tolerability, and pharmacokinetics of NYR-BI03


- DESIGN**
- Randomised, double-blind placebo – controlled, dose escalation design
  - 5 cohorts; 8 participants each cohort; 6:2 active and placebo treatments
  - 3 cohorts will be single ascending doses
  - 2 cohorts will be given continuous infusion doses

- PARTICIPANTS**
- Male and female healthy volunteers
  - 18 – 50 years age



Cohort number	Dose administered
1	Low dose single bolus
2	Medium dose single bolus
3	High dose
4	Low dose continuous infusion (72 hrs)
5	High dose continuous infusion (72 hrs)

- LOCATION & DURATION**
- Study will be conducted at a clinical trial centre in Australia 2H CY2024
  - The study duration will vary between 1 – 4 days



\*trial design subject to ethics approval



Nyrada  
inc

# Cholesterol Lowering Drug Program

---

Novel small molecule PCSK9 Inhibitor



# Cholesterol Lowering Market

## Population, Problem, Opportunity



**62.6 million**

Americans have high cholesterol<sup>1</sup>

**56 million**

between ages 40 and 75  
treatment eligible

**27.4 million**

taking a statin<sup>1</sup>

**18.4 million**

Unable to achieve  
LDL-C target despite taking a statin<sup>1</sup>

**1 in 5 patients**  
statin intolerant<sup>3</sup>

### Global Cholesterol Drugs Market

- USD 18.8 billion in 2021 (USD 14.7 billion statin drugs)<sup>8</sup>
- Est. sales revenue USD 30 billion by 2027 (**CAGR 8%**)<sup>9</sup>

### Drivers of Market Growth

- Increasing rate of high cholesterol in patients
- Awareness of the benefits of cholesterol-lowering drugs
- New treatment options entering the market

# Current PCSK9 Injectable Drugs

## Expensive and Inconvenient



Effective when combined with statin treatment



Expensive US\$5,800 to US\$6,500 per year



Inconvenient for patient / poor compliance



Expensive to manufacture



Insurer / patient co-pay reluctance (US)

**Competitive advantages**  
of a small molecule PCSK9 inhibitor



- **Patient convenience:** once per day oral treatment
- **Lower manufacturing cost**
- Dose form **can be combined with a statin** (single pill)



# Corporate

ASX:NYR



# Financial Overview and Outlook

## FY2023 Highlights and FY2024 Outlook

- Resources:
  - Cash balance of \$3.7M at end of June 2023
  - Cash balance of \$2.3M at end of September 2023
  - R&D Tax Incentive refund of approximately \$3.2M anticipated subject to Government Agency review.
- Programs
  - Advancing Brain Injury program candidate (NYX-BI03) to GLP testing and clinic
  - Cholesterol Lowering program development reset

## Operating Results Summary

	FY2023 (A\$)	FY2022 (A\$)
R&D Costs	6,411,264	1,835,072
Corporate and admin expenses	641,117	699,653
Share-based payment expense	541,214	966,951
Professional services expense	409,523	338,841
Employment benefits expense	1,100,136	1,000,030

# Summary & News Flow



## Brain Injury



- Completion of candidate GLP studies of NYX-BI03
- Expected commencement of Phase I clinical trial for NYX-BI03 H2 CY2024

## Cholesterol Lowering



- Review of analogue library
- Low-cost background works

## Corporate



- Ongoing cost management initiatives
- Non dilutive funding applications in US and AU



---

**Thank you for your attention  
and your support!**

**Questions?**

---

ASX:NYR

## References

---

- 1 Brain Injury Alliance (Connecticut): <http://www.biact.org/understanding-brain-injury/brain-injury-facts-statistics> and US Centers for Disease Control and Prevention: <https://www.cdc.gov/stroke/facts.htm>
- 2 Wong ND et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US. J Clin Lipidology. 2016
- 3 National Academies of Sciences, Engineering, and Medicine 2022. Traumatic Brain Injury: A Roadmap for Accelerating Progress. Washington, DC: The National Academies Press. <https://doi.org/10.17226/25394>
- 4 World Stroke Organisation (WSO): Global Stroke Factsheet 2022, Valery L Feigin et al, International Journal of Stroke 2022, Vol. 17(1) 18–29
- 5 [Global Traumatic Brain Injury Market to 2030 - Insight, Epidemiology and Forecast by ResearchAndMarkets.com](#)
- 6 [Stroke Treatment Market Insight and Trends 2027 - TMR \(transparencymarketresearch.com\)](#)
- 7 'Moderate to Severe Traumatic is a Lifelong Condition', CDC publication available at: [https://www.cdc.gov/traumaticbraininjury/pdf/moderate\\_to\\_severe\\_tbi\\_lifelong-a.pdf](https://www.cdc.gov/traumaticbraininjury/pdf/moderate_to_severe_tbi_lifelong-a.pdf)
- 8 Management of Statin Intolerance in 2018: Still More Questions Than Answers, Toth PP, Patti AM, Giglio RV, Nikolic D, Castellino G, Rizzo M, Banach M. Am J Cardiovasc Drugs. 2018 Jun;18(3):157-173
- 9 [Cholesterol Lowering Drug Market Research Report by Disease Type, Class of Drug, Distribution Channels, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19, July 2022 and Global Statin Market – Industry Trends and Forecast to 2029, Data Bridge Market Research](#)



Brain Injury Solution  
Animation



Cholesterol-Lowering  
Animation



Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board.



ASX:NYR

[info@nyrada.com](mailto:info@nyrada.com)

[www.nyrada.com](http://www.nyrada.com)